Drug Type: Small Molecule
Conditions: ALS, Parkinson’s disease, diabetic neuropathy
Mechanism Type: Microtubule dynamics modulator
Mechanism: Kinemed is developing noscapine and new analogues for neurodegenerative diseases and fibrotic diseases. Noscapine regulates abnormal microtubule (MT) dynamics, and reverses MT-mediated neuronal transport defects. The company has developed a proprietary technology for assessing MT turnover that is being developed as a biomarker in several neurodegenerative diseases, including ALS.
U.S. Status for ALS: Preclinical
 KineMed Receives U.S. Patent Allowance for Noscapine to Treat ALS, Parkinson’s Disease, and Diabetic Neuropathy. BioSpace, 4 Sep 2014. Accessed 9 Mar 2016 from http://www.biospace.com/News/kinemed-inc-receives-u-s-patent-allowance-for/345325.
 Kinemed. Neurodegenerative Diseases. Kinemed, n.d. Accessed 9 Mar 2016 from http://www.kinemed.com/Corporate/Core-Areas/Neuro.aspx.
Last updated March 9th, 2019